03 Jun Circulating Tumor Test May Identify Breast Cancer Patients Who Will Not Benefit From Endocrine Therapy
MedicalResearch.com Interview with:
Daniel F. Hayes, M.D.
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Comprehensive Cancer Center
Ann Arbor MI
Medical Research: What is the background for this study? What are the main findings?
Dr. Hayes: We have developed a circulating tumor cell endocrine therapy index that we hypothesize will identify patients with estrogen receptor positive metastatic breast cancer but who will not benefit from endocrine (anti-estrogen) therapy. We can now semi-quantifiably measure er as well as bcl2, her2, and ki67 in a highly accurate and reproducible fashion. We are now conducting a multi-institutional prospective trial in North America (the Circulating Tumor Cell-Endocrine Therapy COMETI study) to determine if our hypothesis is correct.
Medical Research: What should clinicians and patients take away from your report?
Dr. Hayes: Currently, the Circulating Tumor Cell-Endocrine Therapy has no role in standard clinical practice. If validated, we would hope it could be used to make clinical decisions regarding use of endocrine therapy or not.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Hayes: the COMETI trial is ongoing. We also propose that ctc-phenotyping (such as the ctc-eti) will complement the exciting new field of circulating cell free tumor plasma dna analysis for mutations that may be important in driving cancer behavior.
Citation:
[wysija_form id=”3″]
MedicalResearch.com Interview with: Daniel F. Hayes, M.D., Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Comprehensive Cancer Center, & Ann Arbor MI (2015). Circulating Tumor Test May Identify Breast Cancer Patients Who Will Not Benefit From Endocrine Therapy
Last Updated on June 3, 2015 by Marie Benz MD FAAD